Skip to main content
OpenTrials
Completed

NCT Number: NCT03096405

Impact MRSA -PCR on Patient Management

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).

With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.

The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

MRSA Bacteremia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Groupe Hospitalier Paris Saint Joseph

Paris, Île-de-France Region, 75014, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive

Exclusion criteria

  • Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.

Treatment and study plan

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Diagnostic Test

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Primary outcomes

  1. Adaptation duration of antibiotherapy

    Time frame: 24 hours

Secondary outcomes

  1. Mortality

    Time frame: Day 30

  2. average duration of hospitalization

    Time frame: day 30

Sponsors and collaborators

Lead sponsor

Fondation Hôpital Saint-Joseph

Other

Registry information

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Mar 30, 2017
Registry last updated
May 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.